China National Drug Administration grants rapid approval of Roche ’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - August 20, 2018 Category: Pharmaceuticals Source Type: news

China National Drug Administration grants rapid approval of Roche ’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - August 20, 2018 Category: Pharmaceuticals Source Type: news

Cancer patient who was awarded $289M in Monsanto case speaks out
Dewayne "Lee" Johnson alleges that his use of Monsanto's weed killer Roundup contributed to his non-Hodgkin's lymphoma (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 18, 2018 Category: Consumer Health News Source Type: news

COUNTERPOINT: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?
It is clear that chemoimmunotherapy has redefined the history of follicular lymphoma, producing survival rates measured in decades. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Paul M. Barr, MD Source Type: news

POINT: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?
Balancing the goal of obtaining a durable remission and that of avoiding a negative impact on quality of life argues against the routine use of chemotherapy in follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Loretta J. Nastoupil, MD Source Type: news

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

Burkitt Lymphoma
Title: Burkitt LymphomaCategory: Diseases and ConditionsCreated: 11/20/2015 12:00:00 AMLast Editorial Review: 8/15/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 15, 2018 Category: Cancer & Oncology Source Type: news

Government ministers should ban Roundup – not sing its praises
Th érèse Coffey’s ill-judged tweet shows we have still work to do to rid the planet of the glyphosateOn a summer Sunday afternoon, Th érèse Coffey, parliamentary-under secretary of state at the Department for Environment, Food and Rural Affairs (Defra), was, it would appear from her Twitter feed, about to do some gardening. Unremarkable, you might think. Parliament is in recess, and parliamentarians are entitled to their leisure like anyone else.But this was political gardening, for before doing so she put out a quite remarkable message: “Getting ready to deploy the amazing Roundup!&...
Source: Guardian Unlimited Science - August 14, 2018 Category: Science Authors: Natalie Bennett Tags: Monsanto Pesticides Bayer Agriculture Farming Conservatives Food safety Environment European Union Science Politics Source Type: news

Government ministers should ban Roundup – not sing its praises | Natalie Bennett
Th érèse Coffey’s ill-judged tweet shows we have still work to do to rid the planet of the glyphosateOn a summer Sunday afternoon, Th érèse Coffey, parliamentary-under secretary of state at the Department for Environment, Food and Rural Affairs (Defra), was, it would appear from her Twitter feed, about to do some gardening. Unremarkable, you might think. Parliament is in recess, and parliamentarians are entitled to their leisure like anyone else.But this was political gardening, for before doing so she put out a quite remarkable message: “Getting ready to deploy the amazing Roundup!&...
Source: Guardian Unlimited Science - August 14, 2018 Category: Science Authors: Natalie Bennett Tags: Monsanto Pesticides Bayer Agriculture Farming Conservatives Food safety Environment European Union Science Politics Source Type: news

Davids Wins James O. Armitage Lymphoma Clinical Investigator Award
Matthew S. Davids, MD, MMSc, of the Dana-Farber/Brigham and Women ’s Cancer Center, received the first James O. Armitage Lymphoma Clinical Investigator Award at the 2018 Pan Pacific Lymphoma Conference in Maui, Hawaii, in July. This award acknowledges (Source: BWH News)
Source: BWH News - August 14, 2018 Category: Hospital Management Source Type: news

Monsanto hit with $290 million cancer liability ruling in Roundup (glyphosate) herbicide trial
(Natural News) A San Francisco jury found Monsanto (now owned by Bayer) liable for the glyphosate-induced cancer of Dewayne Johnson, who is dying from non-Hodgkin’s lymphoma. Johnson sprayed glyphosate 20-30 times per year on public school grounds (near children, no less), and he was twice “doused” with glyphosate due to malfunctioning equipment. Monsanto — which... (Source: NaturalNews.com)
Source: NaturalNews.com - August 11, 2018 Category: Consumer Health News Source Type: news

Jury Awards $289 Million to Man Who Blames Monsanto ’s Roundup for Cancer
(SAN FRANCISCO) — A jury’s $289 million award to a former school groundskeeper who said Monsanto’s Roundup left him dying of cancer will bolster thousands of pending cases and open the door for countless people who blame their suffering on the weed killer, the man’s lawyers said. “I’m glad to be here to be able to help in a cause that’s way bigger than me,” Dewayne Johnson said at a news conference Friday after the verdict was announced. Johnson, 46, alleges that heavy contact with the herbicide caused his non-Hodgkin’s lymphoma. The state Superior Court jury agreed tha...
Source: TIME: Health - August 11, 2018 Category: Consumer Health News Authors: Paul Elias / AP Tags: Uncategorized California Cancer onetime Source Type: news

Jury awards $289m damages in Monsanto cancer trial
Former US school groundskeeper says glyphosate weedkillers caused his lymphoma (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 11, 2018 Category: Pharmaceuticals Source Type: news

Jury awards $298m damages in Monsanto cancer trial
Former school groundskeeper says glyphosate weedkillers caused his lymphoma (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 11, 2018 Category: Pharmaceuticals Source Type: news

Routine Lab Testing of Little Value in Surveillance of Aggressive Lymphoma Routine Lab Testing of Little Value in Surveillance of Aggressive Lymphoma
Routine laboratory testing has limited value in the surveillance of aggressive lymphoma in asymptomatic patients in complete remission, researchers from Australia report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 11, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Chemical giant ordered to pay $289M in Roundup cancer trial
"The simple fact is he is going to die," said the attorney who represented Dewayne Johnson, who has non-Hodgkin's lymphoma (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 11, 2018 Category: Consumer Health News Source Type: news

Obinutuzumab/Lenalidomide Combo Safe, Effective in Advanced Follicular Lymphoma
The combination of obinutuzumab and lenalidomide was found to be effective in relapsed or refractory follicular B-cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

New Treatment for Non-Hodgkin Lymphoma Approved
Title: New Treatment for Non-Hodgkin Lymphoma ApprovedCategory: Health NewsCreated: 8/8/2018 12:00:00 AMLast Editorial Review: 8/9/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 9, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves New Drug for Cutaneous T-Cell Lymphomas FDA Approves New Drug for Cutaneous T-Cell Lymphomas
The FDA has granted approval for mogamulizumab-kpkc for adult patients with relapsed or refractory mycosis fungoides or S é zary syndrome.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma
WEDNESDAY, Aug. 8, 2018 -- Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two rare types of non-Hodgkin lymphoma. The drug was approved to treat relapsed or refractory mycosis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 8, 2018 Category: Pharmaceuticals Source Type: news

Anti-CCR4 Agent Gets FDA Thumbs Up for Cutaneous Lymphomas
(MedPage Today) -- First drug approved specifically for rare S é zary syndrome (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 8, 2018 Category: American Health Source Type: news

New Treatment for Non-Hodgkin Lymphoma Approved
WEDNESDAY, Aug. 8, 2018 -- Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two types of non-Hodgkin lymphoma. The drug was approved to treat relapsed or refractory mycosis... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 8, 2018 Category: General Medicine Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or S ézary syndrome after at least one prior systemic therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 8, 2018 Category: American Health Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Researchers Find New Mesothelioma Genes in Family Study
This study strengthens the suspicion that, next to germline BAP1 alterations, other genetic factors might predispose families to the development of MM,” the authors wrote. Mutations in only one gene called BAP1 have been shown to increase risk of mesothelioma. However, experts suspect other genes may play a role in the disease. This new study supports the idea that other genes can predispose a person — or even an entire family — to mesothelioma. Hints of Genetic Influence on Mesothelioma Risk Asbestos exposure is the No. 1 cause of mesothelioma. However, some families seem to have more cases of mesothe...
Source: Asbestos and Mesothelioma News - August 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Increased risk of cancer from breast implants? Woman barely survives rare blood cancer linked to her implants
(Natural News) A 48-year-old British woman survived a rare blood cancer that was triggered by her breast implants. Known as anaplastic large cell lymphoma (ALCL), this type of cancer is said to be a result of a reaction between the white blood cells and the new generation of rough surfaced breast implants introduced a decade... (Source: NaturalNews.com)
Source: NaturalNews.com - August 6, 2018 Category: Consumer Health News Source Type: news

CD19 Antibody MOR208 in Relapsed or Refractory B-Cell NHL CD19 Antibody MOR208 in Relapsed or Refractory B-Cell NHL
MOR208, an Fc-engineered, humanized, CD19 antibody, shows promise in rituximab-refractory B-cell NHL and follicular lymphoma.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Migratory Polyarthritis in Diffuse Large B Cell Lymphoma Migratory Polyarthritis in Diffuse Large B Cell Lymphoma
In this case, the patient presented with lymphadenopathy, macular rash, and migratory polyarthritis involving both upper and lower limb joints. What was the unusual diagnosis?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Carcinogenicity Of Glyphosate Debated At Opening Of Trial Against Monsanto
SAN FRANCISCO - The attorney for a man who claims that Monsanto Co. is responsible for his cancer on July 9 opened a bellwether trial in California state court by contending that the company has known since 1998 that its herbicide Roundup, which contains the active ingredient glyphosate, is connected to non-Hodgkin lymphoma (NHL), yet it failed to warn consumers (DeWayne Johnson v. Monsanto Company, No. CGC 16550128, Calif. Super., San Francisco Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 20, 2018 Category: Medical Law Source Type: news

Judge: Glyphosate Plaintiffs' Experts Are Admissible In Case Against Monsanto
SAN FRANCISCO - A federal judge in California on July 10 ruled that the experts for plaintiffs who have sued Monsanto Co. in multidistrict litigation related to the herbicide Roundup should be admitted because the plaintiffs have presented evidence from which a reasonable jury could conclude that glyphosate, the active ingredient in Roundup, can cause non-Hodgkin lymphoma (NHL) at "human-relevant doses" (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 20, 2018 Category: Medical Law Source Type: news

Acute Kidney Injury in Patients With Cancer
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice —PART 1: PTCL-NOS, FTCL, AITL, ALCL
This two-part series highlights the most important aspects of PTCLs and describes current treatment options and investigative opportunities. Part 1 will cover PTCL not otherwise specified, follicular T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma (ALCL), and breast implant –associated ALCL. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Natalia Pin Chuen Zing, MD, MSc, Thais Fischer, MD, Jasmine Zain, MD, Massimo Federico, MD, Steven T. Rosen, MD Source Type: news

Chemoimmunotherapy Ups PFS in Early-Stage Follicular Lymphoma
TROG 99.03 constitutes “the only high level evidence currently available to guide decision making for this group of patients,” says investigator Michael MacManus. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Lower Risk Of Follicular Lymphoma Transformation With Rituximab Lower Risk Of Follicular Lymphoma Transformation With Rituximab
The risk of transformation of follicular lymphoma is significantly lower with rituximab treatment, according to results from the Aristotle study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 18, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Survival Boost With Maintenance Rituxumab in Follicular Lymphoma
In addition to significant improvements in 5-year OS and PFS with maintenance rituximab, there was a trend toward an association between maintenance and reduced transformation risk. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Combo of RT and Chemoimmunotherapy: Best for Early FL? Combo of RT and Chemoimmunotherapy: Best for Early FL?
For early follicular lymphoma, a randomized study finds that the combination of radiation therapy and chemoimmunotherapy works better than radiotherapy alone. Will this change practice?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Children's Hospital maker space to use STEAM-inspired problem-solving
UPMC Children's Hospital of Pittsburgh will unveil Matt's Maker Space, where patients will be able to engage in STEAM-related problem-solving to both learn and distract them from their illnesses. The space is named to honor 12-year-old Matt Conover who died of non-Hodgkin's lymphoma, and the hospital will host an event at 1 p.m. Tuesday to celebrate its opening with community partners Children's Museum of Pittsburgh, Sen. John Heinz History Center, the Andy Warhol Museum, Mt. Lebanon Schoo l District… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 16, 2018 Category: Biotechnology Authors: Stacey Federoff Source Type: news

Robert Kennedy Jr. launches first lawsuit of thousands against Monsanto alleging herbicide Roundup causes non-Hodgkin’s lymphoma
(Natural News) Environmental attorney Robert F. Kennedy Jr. has filed the first of what he termed “several thousand”  lawsuits against agri-giant Monsanto, alleging that its widely-used herbicide Roundup causes non-Hodgkin’s lymphoma. Jurors in San Francisco heard hours of scientific data about the chemical’s link to the disease, which has a high survival rate after five... (Source: NaturalNews.com)
Source: NaturalNews.com - July 16, 2018 Category: Consumer Health News Source Type: news

There ’s More Good News About Immune Therapies for Cancer
There has been welcome excitement in the cancer field lately about immune-based treatments, which co-opt the body’s own immune system to fight tumors. The so-called immunotherapies have transformed everything from solid cancers like melanoma and lung, to blood cancers like lymphoma and leukemia. In the latest study involving one of the first immunotherapies approved by the Food and Drug Administration, researchers report that an immune-based approach can even help people with advanced melanoma, which has spread to the brain, to live longer. The study, published in Cancer Immunology Research, included more than 2,700 ...
Source: TIME: Health - July 12, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthytime Innovation Health Source Type: news

Targeting tumor-associated acidity in cancer immunotherapy
Checkpoint inhibitors, such as cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) monoclonal antibodies have changed profoundly the treatment of melanoma, renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and bladder cancer. Currently, they are tested in various tumor entities as monotherapy or in combination with chemotherapies or targeted therapies. However, only a subgroup of patients benefit from checkpoint blockade (combinations).07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 11, 2018 Category: Urology & Nephrology Source Type: news

Janssen Provides Update on IMBRUVICA ® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 11, 2018 Category: Pharmaceuticals Source Type: news

Woman's tells of how her itchy skin turned out to be cancer
Lauren Chiarello, 33, from New York City, was diagnosed with Hodgkin's lymphoma in December 2007 after experiencing severe itching. She went into remission but it returned again in 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - July 10, 2018 Category: Consumer Health News Source Type: news

Woman tells how her itchy skin was actually cancer and the warning signs to look out for
Lauren Chiarello, 33, from New York City, was diagnosed with Hodgkin's lymphoma in December 2007 after experiencing severe itching. She went into remission but it returned again in 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - July 10, 2018 Category: Consumer Health News Source Type: news

Woman's tells of how her itchy skin turned out to be cancer
Lauren Chiarello, 33, from New York City, was diagnosed with Hodgkin's lymphoma in December 2007 after experiencing severe itching. She went into remission but it returned again in 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - July 10, 2018 Category: Consumer Health News Source Type: news

Top oncologist to study effect of diet on cancer drugs
Siddhartha Mukherjee says trial is first in a series on ‘rethinking human diets for cancer’A groundbreaking clinical trial on whether diet could boost the effectiveness of cancer drugs is set to be launched by one of the world ’s leading oncologists.The work, led bySiddhartha Mukherjee atColumbia University Medical Center in New York, will investigate whether a high-fat, low-carbohydrate diet could improve outcomes for patients with lymphoma and endometrial cancer.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 6, 2018 Category: Science Authors: Hannah Devlin Science correspondent Tags: Cancer research Medical research Siddhartha Mukherjee Science Diets and dieting Health Source Type: news

Gene Mutations Dictate Treatment in NCI Clinical Trial
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - July 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

EPA official whitewashed glyphosate links to non-Hodgkin lymphoma in order to protect Monsanto profits
(Natural News) The EPA has been caught red-handed whitewashing studies of Monsanto’s cash cow, glyphosate. The federal agency purposely ignored data showing a clear connection between glyphosate and non-Hodgkin’s lymphoma. In addition to ignoring the obvious threat of glyphosate, agency regulators obscured the opinions of the Scientific Advisory Panel, charged with reviewing the EPA’s glyphosate... (Source: NaturalNews.com)
Source: NaturalNews.com - July 3, 2018 Category: Consumer Health News Source Type: news